1.11
+0(+0.00%)
Currency In USD
Previous Close | 1.11 |
Open | 1.13 |
Day High | 1.13 |
Day Low | 1.08 |
52-Week High | 2.4 |
52-Week Low | 0.73 |
Volume | 29,648 |
Average Volume | 184,014 |
Market Cap | 25.42M |
PE | -1.37 |
EPS | -0.81 |
Moving Average 50 Days | 1.09 |
Moving Average 200 Days | 1.16 |
Change | 0 |
If you invested $1000 in Femasys Inc. (FEMY) since IPO date, it would be worth $92.5 as of January 19, 2025 at a share price of $1.11. Whereas If you bought $1000 worth of Femasys Inc. (FEMY) shares 3 years ago, it would be worth $342.59 as of January 19, 2025 at a share price of $1.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
GlobeNewswire Inc.
Jan 16, 2025 1:30 PM GMT
FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addre
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
GlobeNewswire Inc.
Dec 03, 2024 2:00 PM GMT
HRC Fertility to begin providing FemaSeed infertility treatment to patients at centers across CaliforniaATLANTA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet n
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
GlobeNewswire Inc.
Nov 26, 2024 1:30 PM GMT
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patientsATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical